Related Articles
Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus
Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan
Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells
Radiation therapy following targeted therapy in oligometastatic renal cell carcinoma
Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma